Created in 2011 as a spin-out of Cincinnati Children's Hospital Medical Center (CCHMC), Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is in advanced preclinical phase of developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia (BPD) in newborns.
Location: United States, Ohio, Cincinnati
Employees: 11-50
Total raised: $76.9M
Founded date: 2011
Funding Rounds 5
| Date | Series | Amount | Investors |
| 26.08.2026 | - | $50M | - |
| 08.01.2020 | Series C | $15.5M | - |
| 07.03.2017 | - | $6.3M | - |
| 10.09.2014 | Series A | $4.6M | - |
| 03.06.2011 | - | $500K | - |
Mentions in press and media 16
| Date | Title | Description |
| 27.08.2026 | Airway Therapeutics Secures $50 Million for Preterm Infant Lung Therapy | Airway Therapeutics closed a $50 million financing round. This capital injection accelerates late-stage development of zelpultide alfa. The novel biologic aims to prevent bronchopulmonary dysplasia (BPD) in very preterm infants. BPD current... |
| 26.08.2026 | Airway Therapeutics Raises $50 Million To Advance Zelpultide Alfa Phase 2b/3 Trial | Airway Therapeutics has closed a $50 million equity financing to support late-stage development of zelpultide alfa, its recombinant human surfactant protein D therapy being studied to prevent bronchopulmonary dysplasia in very preterm infan... |
| 25.08.2026 | Airway Therapeutics Raises $50M in Funding | Airway Therapeutics, Inc., an Atlanta, GA-based clinical biopharmaceutical company developing new biologic therapies for respiratory, inflammatory, and infectious diseases, raised $50M in funding. The round consisted of $26M previously rais... |
| 26.08.2021 | Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients | |
| 26.03.2021 | Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD) USA - English USA - English | |
| 08.01.2020 | Airway Therapeutics Completes $15.5M Series C Financing | Airway Therapeutics, Inc., a Cincinnati, OH-based biopharmaceutical company developing a new class of biologics for patients with respiratory and inflammatory diseases, closed a $15.5m Series C financing round. The backers were not disclose... |
| 16.08.2018 | 14 Health-Related Companies That Have Raised More Than $100K | It’s not exactly a secret that Queen City is the home to a host of startups. While there are certain trends among those represented in greater Cincinnati — such as, say, branding or consumer good — various industries have found success in t... |
| 20.04.2018 | Term Sheet — Friday April 20 | WHAT’S THE RETURN POTENTIAL OF A $1 CRYPTO? Good morning, Term Sheet readers. Jen Wieczner filling in for Polina today. Follow me on Twitter @jenwieczner or email me at [email protected]. Paid Content Securing the enterprise without ... |
| 07.03.2017 | Airway Therapeutics Closes $6.3M Financing | Airway Therapeutics, a Sharonville, Ohio-based biotechnology company focused on developing new interventions for acute and chronic lung diseases, beginning with premature infants, secured $6.3m in bridge financing. Backers included Cincinna... |
| 12.09.2014 | Airway Therapeutics Raises $4.6M in Series A | CINCINNATI, OH, Biotechnology company working to prevent a debilitating lung condition in extremely premature infants, has secured $4.6 million in Series A financing. >> Click here for more funding data on Airway Therapeutics >... |
Show more